• Mashup Score: 9

    The world’s most important meeting on lymphoid neoplasms – the International Conference on Malignant Lymphoma (ICML), held biannually in Lugano, Switzerland – wraps up tomorrow morning. SWOG lymphoma research and lymphoma researchers have been well represented.

    Tweet Tweets with this article
    • Our @SWOGChair blog: SWOG Scores in Switzerland The world’s most important meeting on lymphoid neoplasms – the International Conf. on Malignant Lymphoma (#18ICML) – ends tomorrow in Lugano. @SWOG lymphoma research & researchers have been well represented. https://t.co/czWajHDWq9 https://t.co/G4ucRxPL9c

  • Mashup Score: 6

    Cancer continues to be a significant international health issue, which demands the invention of new methods for early detection, precise diagnoses, and personalized treatments. Artificial intelligence (AI) has rapidly become a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer care. In this review, we performed a systematic survey of the current status of AI technologies used for cancer diagnoses and therapeutic approaches. We discuss AI-facilitated imaging diagnostics using a range of modalities such as computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, and digital pathology, highlighting the growing role of deep learning in detecting early-stage cancers. We also explore applications of AI in genomics and biomarker discovery, liquid biopsies, and non-invasive diagnoses. In therapeutic interventions, AI-based clinical decision support systems, individualized treatment planning, and AI-f

    Tweet Tweets with this article
    • Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Current AI Technologies in Cancer Diagnostics and Treatment https://t.co/1J2ggZ7Q32 https://t.co/0OJkOiO2gx

  • Mashup Score: 4

    In cancer genomics, there is the realization that some very frequently mutated genes like TP53 or KRAS are extremely hard to approach from a therapeutic perspective. In the realm of cancer treatment, the development of agents capable of transforming these …Breakthroughs in targeting TP53, KRAS, and MTAP mutations are paving the way for histology-agnostic therapies, offering hope for universal, more effective cancer treatments! #CancerResearch #PrecisionMedicine

    Tweet Tweets with this article
    • Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility https://t.co/DEbaQZqvQ6 https://t.co/l4NOWa6wL8

  • Mashup Score: 3

    S2302 results are in, indicating that the answer to that specific question is no, this investigational combination does not significantly improve overall survival (OS) for all patients. But as was clear from the content of two rapid oral abstract presentations at the ASCO 2025 Annual Meeting in Chicago earlier this week, Pragmatica-Lung remains a resounding success, as a proof of concept that incorporating streamlined and pragmatic design elements into large trials can help ensure rapid results that can be generalized to a broad and real-world population.

    Tweet Tweets with this article
    • Our @SWOGChair blog: S2302 Pragmatica-Lung Reports Out at #ASCO25 Although it didn't meet its primary endpoint, @SWOG's S2302 Pragmatica-Lung offers many lessons for future #clinicaltrials that are leaner, faster, more representative @ASCO @CancerResrch https://t.co/TwqKvePLl1 https://t.co/xRD0Z60XFM

  • Mashup Score: 14

    The abstract will be released to the public on June 3, 2025 at 12:00 PM UTC Zeynep Eroglu H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Zeynep Eroglu, James Moon, Yana Najjar, Rupesh Kotecha, Michael Wu, Vadim Spektor, Nikhil Khushalani, Larissa Korde, Elad Sharon, Kenneth Grossmann, John Kirkwood, Jedd Wolchok, Sapna Patel, Hussein Tawbi H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, SWOG Statistical Center, Seattle, WA, UPMC Hillman Cancer Center, Pittsburgh, PA, Miami

    Tweet Tweets with this article
    • Results of the @SWOG S2000 phase 2 trial in patients with symptomatic #melanoma brain metastases are reported today at #ASCO25 in an oral presentation. Late-breaking abstract LBA9507: https://t.co/RWyT37ILwM https://t.co/BfC7kFSyjH

  • Mashup Score: 16

    As part of the meeting’s opening session, Dr. Dawn Hershman, SWOG’s group co-chair-elect, will present the 2025 Karnofsky Science of Oncology Award Lecture (Saturday, May 31, 11 am CT, Hall B1 and livestreamed). The Karnofsky Award, which is ASCO’s highest scientific honor, recognizes oncologists who have made outstanding contributions in cancer research, diagnosis, and/or treatment.

    Tweet Tweets with this article
    • Our @SWOGChair's blog: SWOG at ASCO, 2025 Starting with @DrDawnHershman's Karnofsky Award Lecture in the opening session, the #ASCO25 Annual Meeting features some great @SWOG work in oncology research. https://t.co/R12B6BZQQX https://t.co/YycrxXujuy

  • Mashup Score: 6

    Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by tumor heterogeneity and the occurrence of resistance …

    Tweet Tweets with this article
    • Our #TranslationalMedicine Link of the Week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances https://t.co/uL3yCWwLmV https://t.co/PsaIBKJbnR